The DTD1 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population from human non-small cell lung carcinoma NCI-H1299, with targeted disruption of DTD1. This heterogeneous population carries loss-of-function mutations in DTD1 generated by CRISPR/Cas9. The polyclonal nature avoids cloning artifacts, enabling investigations of DTD1 inactivation on D-aminoacyl-tRNA metabolism and protein quality control in a cancer cell context.
NCI-H1299 is a widely used metastatic lung adenocarcinoma model derived from lymph node metastasis of non-small cell lung carcinoma. These cells display invasive properties and oncogenic signaling typical of advanced lung cancer. This background is ideal for studying metastasis mechanisms and therapeutic responses. Combining DTD1 knockout with this cell line allows exploration of tumor-specific translation fidelity dependencies.
DTD1 encodes D-aminoacyl-tRNA deacylase, which hydrolyzes D-aminoacyl-tRNAs to prevent D-amino acid misincorporation into nascent polypeptides. DTD1 interacts with aminoacyl-tRNA synthetases and tRNAs to ensure protein synthesis fidelity. Its activity is modulated by oncogenic signaling and nutrient status, influencing protein synthesis fidelity and proteotoxic stress. Loss of DTD1 causes accumulation of D-aminoacyl-tRNAs, leading to ribosome-mediated synthesis of aberrant proteins and activation of proteotoxic stress responses. This pathway integrates tRNA metabolism, aminoacyl-tRNA biosynthesis, and protein quality control, with DTD1 as a key surveillance factor.
In NCI-H1299 lung adenocarcinoma cells, DTD1 knockout may significantly impair cellular fitness by promoting the accumulation of D-aminoacyl-tRNAs and consequent proteotoxic stress, potentially revealing cancer-specific vulnerabilities in protein homeostasis. Because oncogenic signaling often drives elevated protein synthesis rates, cancer cells may be particularly sensitive to disruptions in translation fidelity. This knockout model thus offers a valuable platform to dissect how lung cancer cells manage D-aminoacyl-tRNA burden and to investigate whether DTD1 acts as a synthetic lethal target or modulates sensitivity to existing chemotherapeutics.
This polyclonal DTD1 knockout cell product is ideally suited for research into translational fidelity, protein quality control, and cancer cell biology. Representative assays include western blotting and RT-qPCR for expression analysis, tRNA charging assays to monitor D-aminoacyl-tRNA accumulation, protein synthesis fidelity assays using reporter constructs, cell growth assays for proliferation, and drug sensitivity testing to evaluate chemotherapeutic responses. Researchers are encouraged to contact Ascent Research for additional product details and technical support.
